γδ T cells protect against LPS-induced lung injury. 2016

Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
Departments of *Medicine and Pediatrics, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

γδ T lymphocytes are a unique T cell population with important anti-inflammatory capabilities. Their role in acute lung injury, however, is poorly understood but may provide significant insight into lung-protective mechanisms occurring after injury. In a murine model of lung injury, wild-type C57BL/6 and TCRδ(-/-) mice were exposed to Escherichia coli LPS, followed by analysis of γδ T cell and macrophage subsets. In the absence of γδ T cells, TCRδ(-/-) mice developed increased inflammation and alveolar-capillary leak compared with wild-type C57BL/6 mice after LPS exposure that correlated with expansion of distinct macrophage populations. Classically activated M1 macrophages were increased in the lung of TCRδ(-/-) mice at d 1, 4, and 7 after LPS exposure that peaked at d 4 and persisted at d 7 compared with wild-type animals. In response to LPS, Vγ1 and Vγ7 γδ T cells were expanded in the lung and expressed IL-4. Coculture experiments showed decreased expression of TNF-α by resident alveolar macrophages in the presence of γδ T cells that was reversed in the presence of an anti-IL-4-blocking antibody. Treatment of mice with rIL4 resulted in reduced numbers of M1 macrophages, inflammation, and alveolar-capillary leak. Therefore, one mechanism by which Vγ1 and Vγ7 γδ T cells protect against LPS-induced lung injury is through IL-4 expression, which decreases TNF-α production by resident alveolar macrophages, thus reducing accumulation of M1 macrophages, inflammation, and alveolar-capillary leak.

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015334 Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors. T-Cell Antigen Receptor gamma-Chain Gene Rearrangement,T-Lymphocyte Antigen Receptor gamma-Chain Gene Rearrangement,Gene Rearrangement, gamma-Chain T Cell Antigen Receptor,T Cell gamma-Chain Gene Rearrangement,T Lymphocyte gamma-Chain Gene Rearrangement,Gene Rearrangement, gamma Chain T Cell Antigen Receptor,T Cell Antigen Receptor gamma Chain Gene Rearrangement,T Cell gamma Chain Gene Rearrangement,T Lymphocyte Antigen Receptor gamma Chain Gene Rearrangement,T Lymphocyte gamma Chain Gene Rearrangement
D015847 Interleukin-4 A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells. B-Cell Growth Factor-I,B-Cell Stimulatory Factor-1,Binetrakin,IL-4,Mast Cell Growth Factor-2,B Cell Stimulatory Factor-1,B-Cell Growth Factor-1,B-Cell Proliferating Factor,B-Cell Stimulating Factor-1,B-Cell Stimulatory Factor 1,BCGF-1,BSF-1,IL4,MCGF-2,B Cell Growth Factor 1,B Cell Growth Factor I,B Cell Proliferating Factor,B Cell Stimulating Factor 1,B Cell Stimulatory Factor 1,Interleukin 4,Mast Cell Growth Factor 2
D016176 T-Lymphocyte Subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells. T-Cell Subset,T-Cell Subsets,T-Lymphocyte Subset,Subset, T-Cell,Subset, T-Lymphocyte,Subsets, T-Cell,Subsets, T-Lymphocyte,T Cell Subset,T Cell Subsets,T Lymphocyte Subset,T Lymphocyte Subsets

Related Publications

Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
September 2010, The Journal of experimental medicine,
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
September 2021, International journal of biological macromolecules,
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
August 2014, The American journal of pathology,
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
May 2020, The Journal of clinical investigation,
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
March 2018, The Journal of clinical investigation,
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
January 2022, Pharmaceuticals (Basel, Switzerland),
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
February 2023, Cell reports,
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
September 2021, Infection and immunity,
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
February 2013, Molecular therapy : the journal of the American Society of Gene Therapy,
Fabian Wehrmann, and James C Lavelle, and Colm B Collins, and Alex N Tinega, and Joshua M Thurman, and Ellen L Burnham, and Philip L Simonian
January 2023, Frontiers in pharmacology,
Copied contents to your clipboard!